Neostem Research Report by JMP Securites
- 801 views
NeoStem, Inc. (AMEX: NBS; Stock Twits: $NBS) is engaged in the development and manufacturing of cell-based therapies in the U.S. Its January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") ...
NeoStem, Inc. (AMEX: NBS; Stock Twits: $NBS) is engaged in the development and manufacturing of cell-based therapies in the U.S. Its January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") is central to the Company's strategic mission of capturing the paradigm shift to cell therapy. The acquisition of PCT gives NeoStem not only access to a world class contract manufacturing cell therapy company but provides a platform and expertise around the evaluation, development and regulatory requirements to develop autologous, allogeneic, immunomodulatory and vaccine-based therapeutics. NeoStem also holds the worldwide exclusive license to VSEL(TM) Technology, which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use.
Headquartered in San Francisco, JMP Securities was founded in January 2000 in response to the consolidation of established independent research boutiques by large commercial banks. Since the mid-1990s nearly 50 regional investment banks—including San Francisco’s Montgomery Securities, Hambrecht & Quist and Robertson Stephens—have been acquired by major financial institutions. Such industry consolidation has pressured a new breed of bulge-bracket investment banks to compete for large market-capitalization clients and has greatly reduced Wall Street’s focus on the middle market. JMP Securities was formed in the mold of its independent, research-driven predecessors as a growth-oriented, entrepreneurial firm dedicated to serving the needs of small and midsized companies and the institutions that invest in them.
© All Rights Reserved
- Embed Views
- Views on SlideShare
- Total Views